CureTech Ltd. is a biotechnology company developing novel, broad-spectrum, immune modulating products for the treatment and control of cancer.
Building on the broad experience of our team, we have established a well-balanced portfolio of cancer therapies with our lead antibody, pidilizumab (CT-011), in late stage clinical testing. Our products are antibodies and peptide-based vaccines designed to modulate the immune response allowing it to exert its anti-cancer activity in an effective manner. An extensive portfolio of issued patents and pending patent applications worldwide protects all our products and their anticipated medical uses.
Our lead monoclonal antibody, pidilizumab, was shown to effectively attenuate tumor growth and eliminate tumor metastases in a variety of model systems. Phase II studies have shown the efficacy and safety of pidilizumab in diffuse large B cell lymphoma (DLBCL), follicular lymphoma as well as in DIPG, a rare form of pediatric brain cancer. Additional clinical studies are ongoing in multiple myeloma and DLBCL.
In October, 2014, Medivation, Inc. (NASDAQ: MDVN) has licensed exclusive worldwide rights to pidilizumab (CT-011). Under the license agreement, Medivation is responsible for all development, regulatory and commercialization activities for pidilizumab for all indications whereas CureTech is responsible for certain research and development activities as well as for the GMP manufacturing of the antibody.
CureTech is a privately held company with offices and laboratories located in Yavne, Israel.